Status:
COMPLETED
Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
Lead Sponsor:
Pfizer
Conditions:
Cerebral Amyloid Angiopathy
Eligibility:
All Genders
55-90 years
Phase:
PHASE2
Brief Summary
Cerebral Amyloid Angiopathy (CAA) is a condition caused by the build-up of a protein called amyloid, predominantly Aβ40, within the walls of brain blood vessels, especially those blood vessels in the ...
Eligibility Criteria
Inclusion
- Patients diagnosed with probable CAA using the Boston criteria; with no clinical cognitive impairment
- In general good health
Exclusion
- Co-morbid diagnosis of clinically documented Alzheimer's disease or significant cognitive impairment
- Clinically significant syncope, epilepsy, head trauma or clinically significant unexplained loss of consciousness within the last 5 years
- Subject's body weight exceeding 100kg
- Women of childbearing potential.
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2015
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT01821118
Start Date
June 1 2013
End Date
September 1 2015
Last Update
May 10 2017
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA Ronald Reagan Medical Center
Los Angeles, California, United States, 90095
2
MGH Stroke Research Center
Boston, Massachusetts, United States, 02114
3
Boston Medical Center - Menino Pavilion
Boston, Massachusetts, United States, 02118
4
Boston Medical Center - Shapiro Center
Boston, Massachusetts, United States, 02118